FDA Grants Accelerated Approval for Jemperli in Advanced Rectal Cancer

The FDA has granted accelerated approval for Jemperli (dostarlimab-gxly) to treat adults with stage II or III dMMR/MSI-H rectal cancer. This immunotherapy offers a new treatment pathway, potentially allowing some patients to avoid traditional therapies like chemotherapy, radiation, and surgery. The decision is supported by the AZUR-1 clinical trial data, with further results presented at the ESMO Congress.